全文获取类型
收费全文 | 92575篇 |
免费 | 45318篇 |
国内免费 | 266篇 |
专业分类
耳鼻咽喉 | 1972篇 |
儿科学 | 4545篇 |
妇产科学 | 906篇 |
基础医学 | 18309篇 |
口腔科学 | 5419篇 |
临床医学 | 13799篇 |
内科学 | 26025篇 |
皮肤病学 | 8229篇 |
神经病学 | 14495篇 |
特种医学 | 3525篇 |
外科学 | 17029篇 |
综合类 | 155篇 |
现状与发展 | 1篇 |
一般理论 | 24篇 |
预防医学 | 5021篇 |
眼科学 | 1825篇 |
药学 | 7150篇 |
中国医学 | 1228篇 |
肿瘤学 | 8502篇 |
出版年
2023年 | 104篇 |
2022年 | 106篇 |
2021年 | 1859篇 |
2020年 | 5332篇 |
2019年 | 11208篇 |
2018年 | 10594篇 |
2017年 | 11753篇 |
2016年 | 12655篇 |
2015年 | 12810篇 |
2014年 | 12885篇 |
2013年 | 13512篇 |
2012年 | 6025篇 |
2011年 | 5827篇 |
2010年 | 9950篇 |
2009年 | 6097篇 |
2008年 | 3282篇 |
2007年 | 2076篇 |
2006年 | 2031篇 |
2005年 | 1684篇 |
2004年 | 1456篇 |
2003年 | 1322篇 |
2002年 | 1238篇 |
2001年 | 960篇 |
2000年 | 753篇 |
1999年 | 346篇 |
1998年 | 145篇 |
1997年 | 111篇 |
1996年 | 103篇 |
1995年 | 91篇 |
1994年 | 78篇 |
1993年 | 69篇 |
1992年 | 158篇 |
1991年 | 156篇 |
1990年 | 134篇 |
1989年 | 106篇 |
1988年 | 114篇 |
1987年 | 135篇 |
1986年 | 109篇 |
1985年 | 106篇 |
1984年 | 76篇 |
1983年 | 82篇 |
1982年 | 42篇 |
1981年 | 37篇 |
1980年 | 29篇 |
1979年 | 51篇 |
1978年 | 64篇 |
1977年 | 28篇 |
1976年 | 29篇 |
1974年 | 29篇 |
1973年 | 31篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
Lauren E. Wiznia Suneet Bhansali Nooshin Brinster Yasir M. Al‐Qaqaa Seth J. Orlow Vikash Oza 《Pediatric dermatology》2019,36(4):520-523
Well‐known causes of zinc deficiency, also referred to as acrodermatitis enteropathica (AE), include defects in intestinal zinc transporters and inadequate intake, but a rare cause of acquired zinc deficiency discussed here is an iatrogenic nutritional deficiency caused by parenteral nutrition administered without trace elements. While zinc‐depleted parenteral nutrition causing dermatosis of acquired zinc deficiency was first reported in the 1990s, it is now again relevant due to a national vitamin and trace element shortage. A high index of suspicion may be necessary to diagnose zinc deficiency, particularly because early clinical findings are nonspecific. We present this case of acquired zinc deficiency in a patient admitted to a pediatric intensive care unit for respiratory distress and atypical pneumonia, who subsequently developed a severe bullous eruption due to iatrogenic zinc deficiency but was treated effectively with enteral and parenteral zinc supplementation, allowing for rapid re‐epithelialization of previously denuded skin. 相似文献
42.
43.
44.
Lander Pea Merino Ricardo Lpez Almaraz Aitor Fernndez de Larrinoa Marta Rubio Lombraa Maria Rosario Gonzlez‐Hermosa 《Pediatric dermatology》2019,36(6):965-966
Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) is an extremely rare recently described disorder characterized by diffuse congenital skin and gastrointestinal vascular lesions that may be associated with gastrointestinal bleeding and thrombocytopenia. We herein present a case report of multifocal lymphangioendotheliomatosis without thrombocytopenia or extensive extracutaneous involvement (gastrointestinal bleeding). Given the high morbidity and mortality associated with this disease, it is important for clinicians to recognize this disorder in order to select the most appropriate therapeutic approach. 相似文献
45.
46.
47.
Florian Huemer Thomas Melchardt Bettina Jansko Adam Wahida Stefanie Jilg Philipp J. Jost Eckhard Klieser Katja Steiger Teresa Magnes Lisa Pleyer Sigrun Greil‐Ressler Christof Rass Richard Greil Alexander Egle 《European journal of haematology》2019,102(5):437-441
Acute myeloid leukemia (AML) is a disease of the elderly population and survival remains poor after failure of hypomethylating agents (HMA). The BCL‐2 inhibitor venetoclax demonstrated activity as monotherapy and in combination with chemotherapy or HMA in AML. In this case series, patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA were treated with venetoclax within a named patient program at our tertiary cancer center in Salzburg, Austria. Between April 2017 and September 2018, seven patients with sAML received venetoclax therapy. Two out of seven patients achieved a complete remission upon venetoclax initiation with a PFS of 505 days and 352 days and another patient achieved complete peripheral blood blast clearing within nine days after start of venetoclax. Among the venetoclax responders, primary refractory disease to prior HMA therapy was documented, 2 patients harbored IDH1/IDH2 mutations and one patient had an antecedent myeloproliferative neoplasm. High BCL‐2 and/or BIM expression in myeloblasts was found in venetoclax responders and response was significantly associated with overall survival (responders: 364 days versus non‐responders: 24 days, P = 0.018). Venetoclax monotherapy is safe and is able to induce durable responses in elderly patients with secondary AML after treatment failure with HMA. 相似文献
48.
49.